Archives: “Archives”

Creating Insulin Producing Beta Cells That Resist Autoimmune Destruction

Engineering TET2-deficient beta cells that resist autoimmune attack to create replacement cell therapies for type 1 diabetes.

Using Genetically Engineered Models to Study Pre-Autoimmune States

Using the RIP-NINJA mouse model to study how PD-1 regulation in the pancreas prevents autoimmune induction and checkpoint therapy-induced diabetes.

Development of Rationally Designed PD-1 Agonist Biologics for the Treatment of Autoimmune Diseases

Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.

Colton Center for RNA Exploration in Autoimmune Therapeutics (CREATE)

Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab

Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes

Diabetes mellitus—progress and opportunities in the evolving epidemic

Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes

Colton Consortium Sponsors 2025 FASEB Autoimmunity Conference

The Colton Consortium sponsored the 2025 FASEB Autoimmunity Conference in Niagara Falls, a leading international forum dedicated to advancing autoimmune research and fostering collaboration among scientists and clinicians worldwide.